Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 0.0
- Book/Share 0.0
- PB 0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 10321243020.0
- FreeCF/Share 0.0
- PFCF 0
- PE 0
- Debt/Assets 0.0
- DivYield 0
- ROE 0.0
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXEL | RBC Capital Mkts | Outperform | Sector Perform | $45 | $50 | July 8, 2025 |
| Upgrade | EXEL | Stephens | Equal Weight | Overweight | -- | $60 | June 24, 2025 |
| Downgrade | EXEL | Wells Fargo | Overweight | Equal Weight | -- | $36 | Feb. 24, 2025 |
| Upgrade | EXEL | Morgan Stanley | Equal Weight | Overweight | $30 | $40 | Jan. 27, 2025 |
| Downgrade | EXEL | Oppenheimer | Outperform | Perform | -- | -- | Jan. 24, 2025 |
| Downgrade | EXEL | BMO Capital Markets | Outperform | Market Perform | $36 | $40 | Dec. 20, 2024 |
| Downgrade | EXEL | BofA Securities | Buy | Neutral | $35 | $39 | Dec. 17, 2024 |
| Reiterated | EXEL | RBC Capital Mkts | -- | Outperform | $30 | $34 | Oct. 16, 2024 |
| Initiation | EXEL | UBS | -- | Neutral | -- | $30 | Sept. 19, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 8:00 AM EDT Company Participants Christopher Senner - Executive VP & CFO Andrew Peters - Senior Vice President of Strategy Conference Call Participants Robert Burns - H.C.
Read More
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech Equity Research here at the firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL).
Read More
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
Published: September 04, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or "the Company") (NASDAQ: EXEL) for violations of the securities laws.
Read More
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) 2025 Wells Fargo Healthcare Conference September 3, 2025 12:45 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the first session after lunch time.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Read More
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Will EXEL's Share Repurchase Program Boost Value for Investors?
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Read More
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib although the size of the clinical benefit isn't known yet. Zanzalintinib doesn't seem to have outperformed in head and neck cancer, with the company curtailing development in that indication following phase 2 data from STELLAR-305.
Read More
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read More
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).
Read More
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Michael M. Morrissey
- Employees 1147